FDA warns Bausch & Lomb of persistent microbial contamination and poor aseptic controls at its Tampa sterile drug plant.
What happened
FDA inspected Bausch & Lomb's Tampa drug manufacturing facility from March 12 to 20, 2026. FDA found inadequate environmental and personnel monitoring in critical sterile areas, persistent out-of-limit microorganisms in ISO 5 (critical sterile processing) areas from 2023 to 2025, poor aseptic technique, airflow design problems, and inadequate media fills (simulated filling tests), including a July 2025 line 16 media fill failure. FDA reviewed the company's April 10, 2026, response.
What FDA found
FDA said the company's aseptic processing areas and environmental and personnel monitoring were inadequate, including failure to monitor significant locations and use of cracked media, while out-of-limit microbes persisted in critical sterile areas without adequate corrective action.
21 CFR 211.42(c)(10)FDA said operators repeatedly used poor aseptic technique during filling, and the company's media fills were too small to represent commercial batches and failed on line 16 in July 2025.
21 CFR 211.113(b)FDA said the company did not adequately investigate microbiological departures and adverse trends in its water for injection, environmental, and personnel monitoring programs and did not adequately identify microorganisms.
FDA said the restricted access barrier system line had design deficiencies and insufficient barrier protection, and dynamic smoke studies did not show unidirectional airflow protection across multiple lines.
21 CFR 211.42(c)(10)FDA said the quality unit was not enabled to exercise proper authority and the firm did not operate an effective quality system.
21 CFR parts 210 and 211FDA said the drug products are adulterated (not compliant with CGMP) under the Federal Food, Drug, and Cosmetic Act because methods, facilities, or controls did not conform to CGMP.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
What FDA wants
FDA asks Bausch & Lomb to send a written response within 15 business days of receipt, including independent reviews of environmental monitoring and contamination hazards, a remediation plan, investigations of affected batches, testing of retain samples, and proper dynamic smoke studies. FDA also recommends a teleconference after the response to discuss corrective and preventive actions.
Who should pay attention
- drug manufacturers that use aseptic processing
- brands and customers buying sterile prescription or OTC drugs from this Tampa site
- quality teams responsible for environmental monitoring and media fills
This is a summary. Read the original letter on fda.gov.